Evidence mapPaperPMID 21472002Full record

ReviewNature reviews. Cancer2011

Brain metastases as preventive and therapeutic targets.

Patricia S Steeg, Kevin A Camphausen, Quentin R Smith

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 209 papers.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01679743 phase2withdrawnnot on this mapstarted 2012, after this paper: background citation

A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2012 to 2014Enrolled0ConditionsBreast Cancer, Lung Neoplasms, Breast Neoplasms, Lung CancerArmsTrastuzumab, GRN 1005
NCT04193007 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

A Randomized Phase II Trial of Brain Radiotherapy Combined With Targeted Therapy in Patients With Asymptomatic NSCLC Brain Metastasis With Gene Sensitive Mutation

TypeinterventionalSponsorSecond Affiliated Hospital of Nanchang UniversityRan2019 to 2022Enrolled100ConditionsNon Small Cell Lung Cancer, Brain MetastasesArmsmolecular targeted therapies, Brain Radiotherapy
3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 370 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Efficient Migration Assay for Brain Tumor Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  18. Review
  19. Article
  20. Article

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Patricia S SteegNational Cancer Institute, Bethesda, MD 20892, USA. steegp@mail.nih.gov
Kevin A Camphausen
Quentin R Smith
National Cancer Institute · USNational Institutes of Health · USTexas Tech University · US

Funding

The Synergy Between Radiotherapy and Molecularly Targeted AgentsZIASC010373 · DIVISION OF CLINICAL SCIENCES - NCI · 2025 to 2025
$2.0M
Molecular Analysis of Breast Cancer Metastasis to the BrainZIABC010538 · DIVISION OF BASIC SCIENCES - NCI · 2025 to 2025
$1.8M
Pre-clinical Development of Radiation Sensitizers for Patients with GlioblastomaZIASC010372 · DIVISION OF CLINICAL SCIENCES - NCI · 2025 to 2025
$851k
Molecular Analysis of Breast Cancer Metastasis to the BrZ01BC010538 · BASIC SCIENCES · 2003 to 2005
Intramural NIH HHS Z01 BC010538
6 · The paper itself

Abstract

The incidence of metastasis to the brain is apparently rising in cancer patients and threatens to limit the gains that have been made by new systemic treatments. The brain is considered a 'sanctuary site' as the blood-tumour barrier limits the ability of drugs to enter and kill tumour cells. Translational research examining metastasis to the brain needs to be multi-disciplinary, marrying advanced chemistry, blood-brain barrier pharmacokinetics, neurocognitive testing and radiation biology with metastasis biology, to develop and implement new clinical trial designs. Advances in the chemoprevention of brain metastases, the validation of tumour radiation sensitizers and the amelioration of cognitive deficits caused by whole-brain radiation therapy are discussed.

Indexed as

Antineoplastic AgentsBlood-Brain BarrierBrain NeoplasmsHumansAntineoplastic Agents

Identifiers

PMID21472002
PMCPMC7351203
OpenAlexW2009927285

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.